Faculty and Staff Biography

Salama-Noha

Noha Salama

Professor, Pharmaceutics
Pharmaceutical and Administrative Sciences

314.446.8576

Education

Postdoctoral Translational Scholar and Adjunct Clinical Instructor, University of Michigan, College of Pharmacy, Department of Clinical, Social and Administrative Sciences, Ann Arbor, MI.

Postdoctoral Fellow and Research Associate, University of Washington, School of Pharmacy, Department of Pharmaceutics, Seattle, WA.

Ph.D. in Pharmaceutical Sciences; University of Maryland, School of Pharmacy, Department of Pharmaceutical Sciences, Baltimore, MD.

B.Sc. in Pharmaceutical Sciences, Cairo University, Faculty of Pharmacy, Cairo, Egypt.

Specialty

Recent Peer Reviewed Publications:

1.     Muz B, Abdelghafer A, Markovic M, Yavner J, Melam A, Salama NN, Azab AK. Targeting E-selectin to Tackle Cancer Using Uproleselan, Cancers (Basel). 2021 Jan 18;13(2):335. 

2.     Federico C, Alhallak K, Sun J, Duncan K, Azab F, Sudlow GP, de la Puente P, Muz B, Kapoor V, Zhang L, Yuan F, Markovic M, Kotsybar J, Wasden K, Guenthner N, Gurley S, King J, Kohnen D, Salama NN, Thotala D, Hallahan DE, Vij R, DiPersio JF, Achilefu S, Azab AK. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma. Nature Communications 2020 Nov 27; 11(1): 6037. doi: 10.1038/s41467-020-19932-1.

3.     Sun J, Muz B, Alhallak K, Markovic M, Gurley S, Wang Z, Guenthne N, Wasden K, Fiala M, King J, Kohnen D, Salama NN, Vij R, Azab AK. Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma. Cancers (Basel), 2020 Jan 28;12(2):pii: E305.doi  10.3390/cancers12020305.

 4.     Scoville BA, Segal JH, Salama NN*, Heung M, Bleske B, Eyler RF, Mueller BA. Single Dose Oral Ranolazine Pharmacokinetics in Patients Receiving Maintenance Hemodialysis. Ren Fail, 2019 Nov;41(1):118-125.  * Corresponding author

 5.     Adkins D, Ley J, Neupane P, Worden F, Sacco AG, Palka K, Grilley-Olson JE, Maggiore R, Salama NN, Trinkaus K, Van Tine BA, Steuer CE, Saba NF, Oppelt P. Palbociclib, a Selective Cyclin-Dependent Kinase 4/6 Inhibitor, and Cetuximab in Platinum-Resistant Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter Phase 2 Trial. Lancet Oncol, 2019 Sep; 20 (9): 1295-1305.

 6.     Adkins D., Mehan P., Ley J., Siegel MJ, Siegel BA, Dehdashti F, Jiang X, Salama NN, Trinkaus K and Oppelt P. Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study. Lancet Oncol, 2018 Aug; 19(8):1082-1093.

 7.     de la Puente P, Fettig N, Luderer MJ, Jin A, Shah S, Muz B,

Current Research

Dr. Salama focuses on pursuing translational (bench-to- bedside) research in the area of pharmacokinetics and applied biopharmaceutics. She examines factors that influence and improve drug delivery across biological membranes via modulation of drug transporters (primarily efflux transporters like P-gp and BCRP) and the tight junctions. Dr. Salama utilizes diverse experimental techniques that span in vitro cell culture techniques, to preclinical animal models to clinical trials. Dr. Salama’s current research projects focus on drug pharmacokinetics with emphasis on dose adjustments for special populations such as End Stage Renal Disease patients in collaboration with the University of Michigan. In addition to her current research efforts in pharmacokinetics, Dr. Salama works closely on cancer related research with investigators affiliated with multiple units at Washington University Medical School (Division of Medical Oncology, Radiation Oncology Department, and others).

Current Courses, Activities, and Scholarly Interest

Teaching experience spans Pharmaceutics, Biopharmaceutics, Pharmacokinetic principles.